Short-term menopausal hormone therapy for symptom relief: An updated decision model

Archives of Internal Medicine

Volumn 164, Issue 15, 2004, Pages 1634-1640

  Col, Nananda F ^a   Weber, Griffin ^b   Stiggelbout, Anne ^c   Chuo, John ^d   D'Agostino, Ralph ^e   Corso, Phaedra ^f  

^a RHODE ISLAND HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e BOSTON UNIVERSITY   (United States)

^f CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN;

ADULT; ARTICLE; BREAST CANCER; CARDIOVASCULAR DISEASE; CLIMACTERIUM; CLINICAL TRIAL; COLORECTAL CANCER; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HIGH RISK POPULATION; HORMONAL THERAPY; HUMAN; LIFE EXPECTANCY; MENOPAUSAL SYNDROME; MENOPAUSE; META ANALYSIS; OSTEOPOROSIS; PALLIATIVE THERAPY; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; RISK REDUCTION; SHORT COURSE THERAPY; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; VEIN THROMBOSIS;

AFRICAN AMERICANS; CLIMACTERIC; DECISION MAKING; DECISION SUPPORT TECHNIQUES; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; LIFE EXPECTANCY; MARKOV CHAINS; MIDDLE AGED; MORTALITY; NORTH AMERICA; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RISK;

EID: 3843137264     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.164.15.1634     Document Type: Article

References (68)

1. Barrett-Connor E, Hendrix S, Ettinger B. Women's Health and Menopause: A Comprehensive Approach. Bethesda, Md: National Heart, Lung, and Blood Institute; 2002.
2. Writing Group for the Women's Health Initiative I. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
3. McKinlay SM, Jefferys M. The menopausal syndrome. Br J Prev Soc Med. 1974;28:108-115.
4. Kronenberg F. Hot flashes: epidemiology and physiology, Ann N Y Acad Sci. 1990;592:52-86.
5. Speroff L, Symons J, Kempfert N, Rowan J; femhrt Study Investigators. The effect of varying low-dose combinations of norethindrone acetate and ethinyl estradiol (femhrt) on the frequency and intensity of vasomotor symptoms. Menopause. 2000;7:383-390.
6. Daly E, Gray A, Barlow D, McPherson K, Roche M, Vessey M. Measuring the impact of menopausal symptoms on quality of life. BMJ. 1993;307:836-840.
7. Zethraeus N, Johannesson M, Henriksson P, Strand RT. The impact of hormone replacement therapy on quality of life and willingness to pay. Br J Obstet Gynaecol. 1997;104:1191-1195.
8. Col NF, Eckman MH, Karas RH, et al. Patient-specific decisions about hormone-replacement therapy in postmenopausal women. JAMA. 1997;277:1140-1147.
9. Col NF, Pauker SG, Goldberg RJ, et al. Individualizing therapy to prevent long-term consequences of estrogen deficiency in postmenopausal women. Arch Intern Med. 1999;159:1458-1466.
10. National Center for Health Statistics. Vital Statistics of the United States, 1999: Volume 2, Mortality, Part B. Hyattsville, Md: National Center for Health Statistics; 2001.
11. Gail MK, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81:1879-1886.
12. D'Agostino RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham Study [published correction appears in Am Heart J. 2002;143:21]. Am Heart J. 2000;139:272-281.
13. D'Agostino RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham Study [published correction appears in Am Heart J. 2002;143:21]. Am Heart J. 2000;139:272-281.
14. D'Agostino RB, Wolf PA, Belanger AJ, Kannel WB. Stroke risk profile: adjustment for anti hypertensive medication: The Framingham Study. Stroke. 1994;25:40-43.
15. Ries LAG, Eisner MP, Kosary CL, et al. SEER Cancer Statistics Review, 1973-1999. Bethesda, Md: National Cancer Institute; 2002.
16. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-1847.
17. Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA, 2001;285:2486-2497.
18. Beral V, Banks E, Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet. 2002;360:942-944.
19. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. JAMA. 2002;288:872-881.
20. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA. 2003;289:3243-3253.
21. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351:1451-1467.
22. Ravdin PM, Siminoff LA, Davis GJ, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol. 2001;19:980-991.
23. Ravdin PM. A computer program to assist in making breast cancer adjuvant therapy decisions. Semin Oncol. 1996;23(1, suppl 2):43-50.
24. McCready DR, Chapman JA, Hanna WM, et al. Factors affecting distant disease-free survival for primary invasive breast cancer: use of a log-normal survival model. Ann Surg Oncol. 2000;7:416-426.
25. Negri E, Tzonou A, Beral V, et al. Hormonal therapy for menopause and ovarian cancer in a collaborative re-analysis of European studies. Int J Cancer. 1999;80:848-851.
26. Riman T, Dickman PW, Nilsson S, et al. Risk factors for invasive epithelial ovarian cancer: results from a Swedish case-control study. Am J Epidemiol 2002;156:363-373.
27. Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA. 2001;285:1460-1465.
28. Jacobsen SJ, Goldberg J, Miles TP, Brody JA, Stiers W, Rimm AA. Race and sex differences in mortality following fracture of the hip. Am J Pub Health. 1992;82:1147-1150.
29. Reno J, Burlington H. Fractures of the hip: mortality survey. Am J Surg. 1958;95:581-592.
30. Egol KA, Koval KJ, Zuckerman JD. Functional recovery following hip fracture in the elderly. J Orthop Trauma. 1997;11:594-599.
31. Zuckerman JD. Hip fracture. N Engl J Med. 1996;334:1519-1525.
32. McGovern PG, Jacobs DR Jr, Shahar E, et al. Trends in acute coronary heart disease mortality, morbidity, and medical care from 1985 through 1997: the Minnesota heart survey. Circulation. 2001;104:19-24.
33. Gresham GE, Kelly-Hayes M, Wolf PA, Beiser AS, Kase CS, D'Agostino RB. Survival and functional status 20 or more years after first stroke: the Framingham Study. Stroke. 1998;29:793-797.
34. Davey Smith G, Neaton JD, Wentworth D, Stamler R, Stamler J. Mortality differences between black and white men in the USA: contribution of income and other risk factors among men screened for the MRFIT: MRFIT Research Group: Multiple Risk Factor Intervention Trial. Lancet. 1998;351:934-939.
35. Kuntz KM, Weinstein MC. Life expectancy biases in clinical decision modeling. Med Decis Making. 1995;15:158-169.
36. Sarasin FP, Eckman MH. Management and prevention of thromboembolic events in patients with cancer-related hypercoagulable states: a risky business. J Gen Intern Med. 1993;8:476-486.
37. Fryback DG, Dasbach EJ, Klein R, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making. 1993;13:89-102.
38. Read JL, Quinn RJ, Berwick DM, Fineberg HV, Weinstein MC. Preferences for health outcomes: comparison of assessment methods. Med Decis Making. 1984;4:315-329.
39. Hummel S, Piercy J, Wright R, Davie A, Bagust A, McMurray J. An economic analysis of the Survival and Ventricular Enlargement (SAVE) Study: application to the United Kingdom. Pharmacoeconomics. 1997;12:182-192.
40. Tsevat J, Goldman L, Lamas GA, et al. Functional status versus utilities in survivors of myocardial infarction. Med Care. 1991;29:1153-1159.
41. Post P, Stiggelbout A, Wakker P. The utility of health states after stroke: a systematic review of the literature. Stroke. 2001;32:1425-1429.
42. Jansen SJ, Stiggelbout AM, Wakker PP, Nooij MA, Noordijk EM, Kievit J. Unstable preferences: a shift in valuation or an effect of the elicitation procedure? Med Decis Making. 2000;20:62-71.
43. McLachlan SA, Pintilie M, Tannock IF. Third line chemotherapy in patients with metastatic breast cancer: an evaluation of quality of life and cost. Breast Cancer Res Treat. 1999;54:213-223.
44. Ashby J, O'Hanlon M, Buxton MJ. The time trade-off technique: how do the valuations of breast cancer patients compare to those of other groups? Qual Life Res. 1994;3:257-265.
45. Norum J, Vonen B, Olsen JA, Revhaug A. Adjuvant chemotherapy (5-fluorouracil and levamisole) in Dukes' B and C colorectal carcinoma: a cost-effectiveness analysis. Ann Oncol. 1997;8:65-70.
46. Stiggelbout AM, Kiebert GM, Kievit J, Leer JW, Habbema JD, De Haes JC. The "utility" of the Time Trade-Off method in cancer patients: feasibility and proportional Trade-Off. J Clin Epidemiol. 1995;48:1207-1214.
47. Gatta G, Capocaccia R, Sant M, et al. Understanding variations in survival for colorectal cancer in Europe: a EUROCARE high resolution study. Gut. 2000;47:533-538.
48. Ness RM, Holmes AM, Klein R, Dittus R. Utility valuations for outcome states of colorectal cancer. Am J Gastroenterol. 1999;94:1650-1657.
49. Gabriel SE, Kneeland TS, Melton LJ III, Moncur MM, Ettinger B, Tosteson AN. Health-related quality of life in economic evaluations for osteoporosis: whose values should we use? Med Decis Making. 1999;19:141-148.
50. Torrance GW. Social Preferences for Health States: an empirical evaluation of three measurement techniques. Socio-Economic Planning Sciences. 1976;10:129-136.
51. MacLennan A, Lester S, Moore V. Oral estrogen replacement therapy versus placebo for hot flushes: a systematic review. Climacteric. 2001;4:58-74.
52. Hunt K. Perceived value of treatment among a group of long-term users of hormone replacement therapy. J R Coll Gen Pract. 1988;38:398-401.
53. Barnabei VM, Grady D, Stovall DW, et al. Menopausal symptoms in older women and the effects of treatment with hormone therapy. Obstet Gynecol. 2002;100:1209-1218.
54. Lerman C, Trock B, Rimer BK, Boyce A, Jepson C, Engstrom PF. Psychological and behavioral implications of abnormal mammograms. Ann Intern Med. 1991;114:657-661.
55. Brett J, Austoker J. Women who are recalled for further investigation for breast screening: psychological consequences 3 years after recall and factors affecting re-attendance. J Public Health Med. 2001;23:292-300.
56. Gram IT, Lund E, Slenker SE. Quality of life following a false positive mammogram. Br J Cancer. 1990;62:1018-1022.
57. Gilbert FJ, Cordiner CM, Affleck IR, Hood DB, Mathieson D, Walker LG. Breast screening: the psychological sequelae of false-positive recall in women with and without a family history of breast cancer. Eur J Cancer. 1998;34:2010-2014.
58. Scaf-Klomp W, Sanderman R, van de Wiel HB, Otter R, van den Heuvel WJ. Distressed or relieved? psychological side effects of breast cancer screening in the Netherlands. J Epidemiol Community Health. 1997;51:705-710.
59. Johnston K, Brown J, Gerard K, O'Hanion M, Morton A. Valuing temporary and chronic health states associated with breast screening. Soc Sci Med. 1998;47:213-222.
60. Akman SA, Doroshow JH, Dietrich MF, Chlebowski RT, Block JS. Synergistic cytotoxicity between menadione and dicumarol vs murine leukemia L1210. J Pharmacol Exp Ther. 1987;240:486-491.
61. Stamler J, Stamler R, Neaton JD, et al. Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy: findings for 5 large cohorts of young adult and middle-aged men and women. JAMA. 1999;282:2012-2018.
62. O'Connor AM, Mulley AG Jr, Wennberg JE. Standard consultations are not enough to ensure decision quality regarding preference-sensitive options. J Nat Cancer Inst. 2003;95:570-571.
63. Jansen SJ, Stiggelbout AM, Wakker PP, et al. Patients' utilities for cancer treatments: a study of the chained procedure for the standard gamble and time tradeoff. Med Decis Making. 1998;18:391-399.
64. Jansen SJ, Stiggelbout AM, Nooij MA, Noordijk EM, Kievit J. Response shift in quality of life measurement in early-stage breast cancer patients undergoing radiotherapy. Qual Life Res. 2000;9:603-615.
65. Shumaker SA, Legault C, Thal L, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003;289:2651-2662.
66. Mishra G, Brown W, Dobson A. Physical and mental health: changes during menopause transition. Qual Life Res. 2003;12:405-413.
67. Simon JA, Stevens RE, Ayres SA, Phelps KV. Perimenopausal women in estrogen vasomotor trials: contribution to placebo effect and efficacy outcome. Climacteric. 2001;4:19-27.
68. Speroff L, Whitcomb RW, Kempfert NJ, Boyd RA, Paulissen JB, Rowan JP. Efficacy and local tolerance of a low-dose, 7-day matrix estradiol transdermal system in the treatment of menopausal vasomotor symptoms. Obstet Gynecol. 1996;88:587-592.